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The voice is an important source of communication. Voice disorders, dysphonia, has an 
estimated 30 percent lifetime prevalence in the United States with a significant economic 
and social cost. Severe vocal fold scarring can lead to persistent dysphonia, has no 
optimal treatment and negatively impacts those affected by impairing their quality of life 
and general health. We propose a novel approach to treating sever vocal fold scarring by 
replacing the entirety of the vocal fold mucosa with a tissue engineered implant, the cell-
based outer vocal fold replacement (COVR). We hypothesized that intermediate and 
long-term implantation of human stem-cell derived COVR implants would lead to 
regeneration of vocal fold epithelium and lamina propria and establish an extracellular 
matrix (ECM) approximating normal parameters. We aimed to assess the development of 
these structures by assessing active factors in wound healing including white blood cell 
presence, collagen and fibrin deposition, and glycosaminoglycan incidence. We resected 
the vocal fold mucosa and implanted COVR gels, COVR gel components including a 
decellularized gel scaffold (DECELL) and human-derived adipose stem-cell injection 
(hASC Injection), or performed no treatment following intervention (SCAR) in 49 New 
 
   
 
Zealand white rabbits with intermediate, 6-weeks, postoperative recovery and three 
Yucatan Mini Pigs with long-term, 6 months, post-operative recovery prior to laryngeal 
harvest. Vocal folds were sectioned and assessed through light microscopy, fluorescent 
microscopy, and/or nonlinear scanning laser microscopy (NLSM) to assess outcomes of 
the intervention. Analysis of light microscopy of the intermediate implantation groups 
showed that the COVR implantation had the lowest levels of collagen deposition (50% in 
COVR, 67% in DECELL, 82% in hASC Injection, and 83% in SCAR), greatest 
glycosaminoglycan incidence (50% in COVR, 8% in DECELL, 9% in HASC injection, 
and 25% in SCAR), equivalent white cell presence (50% in COVR, 83% in DECELL, 
45% in hASC Injection, and 42% in SCAR) at laryngeal harvest. Additionally, 
fluorescent microscopy showed persistence of HLA-staining cells in the COVR and 
hASC Injection groups and none in the DECELL or SCAR treatment groups. NLSM 
imaging of the long-term implantation of COVR showed increased collagen deposition in 
the superficial lamina propria in the hASC Injection group, while the SCAR had no 
change in collagen levels, and the COVR implant animal had decreased collagen levels 
compared to untreated control folds. The superficial lamina propria also had increased 
elastin deposition in the COVR group, decreased levels in the SCAR animal, and no 
change in the hASC Injection animal. In the rabbits, COVR implantation promotes 
improved healing and decreased scarring at six weeks, as evidenced by increased 
glycosaminoglycan deposition and decreased collagen development. Additionally, there 
is evidence of xenograph ASC grafts persist for several weeks with continued 
immunomodulatory effects. Our data suggest decreases of overall elastin levels are a 
more sensitive marker of fibrosis in NLSM imaging than increases in collagen levels.   
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The voice is an important source of communicating between people. It is vitally 
important for many professions in addition for typical socialization through verbal 
communication. Voice disorders, or dysphonia, annually affects an estimated 1.7 percent 
of population in the United States, over 5.5 million people, and has an estimated 30 
percent lifetime prevalence.1,2 There is also a substantial cost to diagnosing, managing, 
and treating patients with dysphonia, estimated at 12 billion dollars annually.3 The 
diagnosis for a majority of these cases is acute laryngitis, however a significant portion of 
dysphonia etiologies arise from benign vocal fold lesions (ie. polyps, nodules) and 
malignant neoplasms.1 Patients who have damaged vocal fold tissue, either through 
benign lesions, trauma, or surgical resection, can develop persistent dysphonia due to 
vocal fold scarring. Severe scarring leaves those afflicted with impaired phonation 
including chronically hoarse voice, vocal fatigue, and risks or ends professional careers.4 
Dysphonia has been described by patients as impairing their quality of life, 
impacting their work performance and employment, and has also been associated with 
depression.5-9 Voice disorders have also been found to profoundly affect general health 
impacting the mental, global and social health independent of and with greater 
association than other life-threatening comorbid pathologies including malignancy, 
pulmonary, cardiac disease.10 Thus it has been suggested that the effects of dysphonia 
and subsequently the allocated budgets for treatment is lacking. To make matters worse, 
treatment options for dysphonia are imperfect. In the case of severe vocal fold scarring, 
there is no optimal treatment.  
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Physiology of the Vocal Fold 
To understand the difficulty of finding a treatment for severe vocal fold scarring, 
it is important to understand the physiology of the vocal folds. The vocal folds are paired 
symmetric structures within the larynx. Each vocal fold is made of three-layers: the non-
keratinized stratified squamous epithelium, lamina propria, and muscle. In the human 
vocal fold, the lamina propria is subdivided into three distinct layers based on the 
amounts of collagen and elastic fibers in each layer.11,12  The lamina propia layers are the 
superficial, intermediate, and deep lamina propria. The superficial lamina propria has a 
higher proportion of elastin and a narrow band of collagen. Whereas the intermediate and 
deep layers of lamina propria together form the ‘vocal ligament’ or ‘elastic conus,’ which 
has densely organized collagen.12 Other mammal vocal folds including the rabbit, pig, 
and canine, common animal models used for vocal fold research, have a two-layer lamina 
propria, the superficial and deep layers only.13,14 The vocal fold layers in cross-section 
can be found in Figure 1.15 
‘Body-cover’ theory – ‘Body’ explained 
The landmark ‘body-cover’ theory, originally proposed by Hirano et al. in 1974, 
describes a functional distinction of the vocal fold based on the interactions between 
these two structures. In his theory, Hirano describes the ‘body’ consisting of the vocal 
conus and underlying musculature, primarily the thyroarytenoid muscle, which work 
together as a functional unit. The shape and structure of the ‘body’ is further influenced 
by the vocalis and cricothyroid muscles, external to the vocal fold proper. This in turn, 
alters the mechanical properties of the vocal folds including position, shape, and tension, 
ultimately affecting the quality of phonations produced.  
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 ‘Body-cover’ theory – ‘Cover’ explained 
The ‘cover’ is the mucous membrane which sits on the ‘body’ and is comprised of 
both the superficial lamina propria and overlying squamous epithelium. This ‘cover’ is 
the vibratory layer of the vocal fold. The superficial lamina propria is particularly 
important for its role in vibration. The biomechanics of vibration rely on the superficial 
lamina propria’s extracellular matrix (ECM) protein composition, the concentrations of 
proteoglycans and glycosaminoglycans and their relative densities, to maintain the 
pliability and elasticity necessary for phonation.16 Of these, the glycosaminoglycan, 
hyaluronic acid, has been identified as having the greatest influence on maintaining the 
viscoelasticity properties necessary for normal phonation.16-18  
The biomechanics involved in the production of phonation underly the importance 
of appropriate structure and pliability of the vocal folds. The cover portion of the vocal 
fold vibrates over the body in a mucosal wave motion to create phonation.19 During 
normal phonation, the vocal folds will oscillate and collide in an incredible range of 20Hz 
to 3kHz, with an average fundamental frequency of an adult male around 100 Hz and an 
adult female at 200 Hz.20,21  Unlike other specialized stratified squamous epithelium, the 
vocal cords withstand cyclical tensile, shear, and impact tissue stress requiring continual 
repair of the epithelium while maintaining its viscoelastic properties.22 An in depth 
discussion on the mechanism of phonation including acoustics and biomechanics of vocal 
fold oscillations is beyond the scope of this project. However, it should be noted that 
finding an optimal treatment for vocal fold scarring requires a robust replacement able to 
withstand the stresses of normal vibratory function.  
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Pathophysiology of Vocal Fold Scarring 
Despite the vocal folds impressive ability to heal, both normal and impaired 
healing can lead to fibrosis of the vocal folds. While incidence and prevalence statistics 
of vocal fold scarring is still lacking in the literature, vocal fold scarring and resultant 
dysphonia has been studied for nearly 30 years.23 The pathophysiology of vocal fold 
scarring has been illuminated in this time. 
Causes of vocal fold scarring can be divided between two sources of damage: 
trauma (e.g. phonotrauma from overuse, intubation, iatrogenic during surgery) or 
inflammation (e.g. laryngitis, exposure to environmental irritants, laryngopharyngeal 
reflux).24-30 In particular, vocal fold damage and scar formation due to squamous cell 
carcinoma of the vocal fold and iatrogenic damage to the vocal fold during laryngeal 
cancer resection can lead to significant scar formation.31  
The microstructure of the vocal fold scar tissue has been of particular interest in 
scar formation and treatment options. Histologic analysis of scarred folds has 
demonstrated fibrotic changes in the extracellular matrix (ECM) particularly evident in 
the lamina propria. These include deposition of excessive and disorganized collagen, loss 
of elastin fibers, and changes in hyaluronic acid, fibronectin, and procollagen 
densities.25,32-34. Collagen deposition and loss of elastin affects the mechanical properties 
of the vocal fold, such that the cover layer stiffens and is unable to form a mucosal wave 
impairing optimal vibration. Additionally, severe scar formation can undergo a cicatricial 
process which leads to loss of vocal fold bulk in the affected fold that then causes glottal 
insufficiency, such that the two folds are not able to collide.35,36 Together, these changes 
to the vocal fold ECM manifest into difficulty phonating properly and appear clinically as 
dysphonia.  
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Current Literature for Scar Treatment 
Together with the longstanding interest in the pathophysiology of vocal fold scars, 
treatment options have been studied.  Non-surgical interventions to improve dysphonia 
include voice therapy. As a treatment it has had questionable success for non-organic 
vocal dysphonia, such as with phonotrauma, but lacks evidence of efficacy for severe 
vocal fold scarring.37-39  
Surgical intervention has instead become the treatment regimen of choice for 
severe scar tissue. Phonosurgery, microsurgery of the vocal folds to improve vocal 
qualities, was the initial surgical option for vocal fold scarring and has continued to 
improve with technological advancements, yet has inconsistent, often suboptimal 
results.37,40 Additionally, surgical interventions have extended recovery periods, up to one 
year, in order to achieve maximum effect with ongoing voice rest and rehabilitation 
needed during recuperation.38,41 The requirements of recuperating from cold steel surgical 
interventions with unpredictable, unsatisfactory results following scar resection has 
created fertile ground of research in laryngology to find a more suitable treatment option. 
Treatments involving injectable therapies to bolster results of surgery have been 
studied concurrently with direct surgical intervention. These treatments have many 
benefits in common, including the ability to provide in-office injections, ease of use, cost-
effectiveness, and availability of the injectable substances.42 Steroid injections directly 
into the scarred vocal fold is a common first-line treatment for vocal fold scars. Steroids 
are thought to control the inflammatory response by modifying cytokine secretion, but 
there is limited evidence that they are an effective treatment for severe vocal fold 
scarring.43-45 Furthermore, inflammation and wound healing can cause contracture of the 
vocal fold, as mentioned previously, which can be worsened by the steroid’s atrophic 
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effects on the vocal folds.45 Research into injectables materials that ameliorate these side 
effects has steadily continued. Biologic materials including fascia, autologous fat, and 
collagen, commonly used for augmentation and medialization of the vocal fold, have 
been attempted to improve vocal scarring with minimal desired effects.46-49 As such, 
while steroid injections and biologic material injections currently make up the common 
treatment for vocal fold scarring, they leave much to be desired in terms of outcomes. 
Bioactive chemicals found in the normal ECM of the vocal cord mucosa have also 
been studied extensively as a treatment for vocal fold scarring. The glycosaminoglycan, 
hyaluronic acid (HA), was initially found to be important for scarless wound healing in 
fetuses, and given its active properties functionally and biologically has become an active 
area of research and treatment modality.50-52  HA within the vocal fold minimizes the 
mechanical stress of the folds during oscillations, acting as a shock absorber and tissue 
damper.53,54 HA also has immunomodulating properties important for cell migration and 
wound healing.50 HA has been used to prevent vocal scar formation following injury.55-57 
Finck et al. 2010 reported on long-term outcomes of esterified HA gels implanted 
following surgical resection of scar, with improvements in vocal fold videostroboscopy 
assessments, including vibration amplitude, mucosal wave symmetry, glottic gap, and 
voice quality assessments.58 Provided its perceived and documented benefits, future 
therapies that incorporate HA as a component are highly likely.  
The development and growth of regenerative medicine–constructing tissue to 
replace or repair existing tissue–has led to the creation of sophisticated materials that can 
be used to repair scarred vocal folds and regenerate the ECM microstructure. Synthetic 
polymer scaffolds, cell transplantation, growth factor injections, and other state-of-the-art 
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biomaterials have created additional opportunities to find a solution for regenerating the 
larynx with varying success. 59-63 These studies are too numerous to include here, 
however cell therapies within the folds have included pluripotent stem cells, 
mesenchymal stem cells, and fibroblasts. Pre-clinical in vitro animal studies have shown 
that adipose-derived mesenchymal stem cells have multiple applications within the 
larynx, including becoming cartilage-like grafts, developing into lamina propria, 
epithelium, and ECM.64-66  
Cell and biologic therapies have shown the greatest promise, with some therapies 
advancing to human clinical trials. Hirano et al. 2017 injected hepatocyte growth factor 
into the vocal folds for four weeks with assessment at six months post-procedure. They 
found treatment to be safe and effective, with significant improvement in objective 
(maximum phonation time, vocal fold amplitude) as well as subjective (voice handicap 
index-10 [VHI], voice grading and expert voice quality assessment) findings.67 Ma et al. 
2019 injected autologous cultured fibroblasts in patients with vocal fold scarring and age-
related atrophy, these patients then received graded assessments at four, eight, and twelve 
months. Treatment groups had significantly improved mucosal waves at four and eight 
months, and improved vocal quality, assessed by professional voice raters, at twelve 
months.68 Hertegård et al. 2020, injected bone-marrow derived autologous mesenchymal 
stem cells following scar resection. This also showed safety and efficacy improving 
vibration and elasticity at one year, along with improvement in subjective patient 
surveys.69 These studies have focused on the introduction of a single component to 
improve the vocal fold repair through immunomodulation of the healing process through 
either direct introduction to scar tissue or following scar tissue resection. 
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Introduction to COVR 
This laboratory instead proposes a novel approach of replacing the entire vocal 
fold mucosa. To this end, we developed the cell-based outer vocal fold replacement 
(COVR) implant, a tissue-engineered treatment designed to be implanted directly 
following removal of native scarred vocal folds.70 The COVR implant is created from a 
multipotent adipose-derived mesenchymal stem cell tissue embedded within a three-
dimensional fibrin gel scaffold. Previous work by this laboratory has shown the 
epithelization by adipose-derived stem cells to create a bi-layered structure similar to the 
epithelium and lamina propia.64 Additionally, this structure was found to exhibit 
biomechanical and functional vibration mechanics suitable for vocal fold structure 
replacement.65  
Long et al. 2018 showed initial success of COVR implantation within an in vivo 
rabbit study.70 This pilot study involved unilateral cordectomy of sixteen rabbits within 
three treatment arms: fibrin glue alone, autologous mucosal replants of vocal fold tissue 
and COVR implants. Four weeks after surgery the rabbits were euthanized, and larynges 
harvested. The COVR treatment group achieved excellent graft implantation, 
regeneration of vocal fold epithelium and lamina propria, and induced phonation as 
determined histologically and by mucosal wave symmetry, respectively. Importantly, at 
this timepoint the COVR ECM structure remained immature with impaired vibration 
compared to the mucosal transplant treatment group. 
The structure of the ECM, particularly changes to the fibrin and collagen 
deposition within the lamina propria, have been found to reflect the degree of damage 
and healing of the vocal folds. Previous COVR implant larynges were harvested at four 
weeks and had immature ECM with mature elastic fibers not identified within the implant 
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sites and diminished mucosal-polysaccharide staining when compared to mucosal 
replants. It is possible that additional post-operative recovery time would allow for ECM 
maturity and therefore regenerate a more normal composition.  
Statement of Purpose and Specific Aims 
The goal of this project was to identify the intermediate and long-term outcomes 
of human-derived stem cell COVR implants within animal models. We included a large 
animal model with a COVR implant developed using human stem cells and long-term 
follow up to create realistic conditions of the COVR implant as a future human 
therapeutic. 
We hypothesized that both intermediate and long-term implantation of human cell 
based COVR will also lead to regeneration of the vocal fold epithelium and lamina 
propria and establish an ECM structure that approximates normal ECM structure.  
AIM 1:  
The assessment of the development of the epithelium, lamina propria, and the 
ECM following intermediate-term implantation of COVR in vocal folds through 
histology. We determined intermediate effects in COVR implants compared to individual 
components of the COVR implant by assessing active factors in wound healing, such as 
white blood cell presence, collagen and fibrin deposition, and glycosaminoglycan 
incidence. 
AIM 2:  
To develop a large, voicing animal model for the assessment of longer term 
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METHODS 
All animal activities were done in accordance with the Institutional Animal Care 
Committee, following USDA guidelines for animal ethics and under veterinarian 
supervision.   The protocols of the studies were submitted to and approved by the UCLA 
Animal Research Committee IRB.  
COVR development 
Human adipose-derived stem cells (hASC) were used to construct the COVR 
implants. For development of rabbit COVR gels, rabbit fibrinogen was used, and pig 
fibrinogen was used for pig COVR gels. Otherwise, production of COVR gel implants 
were equivalent for both groups. Size of the implant was adjusted for the two species, 
with rabbits receiving one-half a gel per vocal fold, and pigs receiving a whole gel. 
As described previously, COVR development used animal-specific fibrinogen, 
bovine thrombin, and hASC in suspension were mixed in a 4:1:1 ratio.70,71 Final hASC 
content was of 6x105 cells/gel. The mixture was placed within a 12 mm Corning 
Transwell culture insert to create fibrin gels embedded with ASC. Total volume was 900 
ul per gel. Following gelation, additional hASC were pipetted onto the surface to emulate 
the epithelial layer. The insert conserved the air interface on the hASC covered surface of 
the gel intended to become the epithelial layer and media diffused through the remainder 
of the gel. The COVR gels were incubated and maintained with culture medium 
containing 10% fetal bovine serum and 10 ng/mL epidermal growth factor for 2 weeks. 
Media was replaced every 2-3 days.  
Decellularized Gel (DECELL) development 
DECELL production was identical to initial COVR development. Following the 2 
weeks of incubation, the COVR gel was placed in sterile Sodium Dodecyl Sulfate (SDS) 
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1% solution on a shaker for 3 days, with daily solution changes. DECELL gels were then 
washed for 24 hours with sterile saline prior to implantation.  
Rabbit Laryngeal Surgery and COVR Implantation  
49 New Zealand white rabbits, weighing 3-3.5 kg, underwent survival surgeries as 
described previously.70-72 Anesthetization was achieved with combined mask and 
chemical induction and maintenance on isoflurane. In brief, a vertical midline neck 
incision was made to expose the larynx and trachea. A lower tracheostomy was 
performed, and pediatric endotracheal tube was placed to maintain intra-operative 
anesthesia. A laryngofissure through the midline thyroid cartilage exposed the vocal 
folds. A cordectomy meeting the definition of a European Laryngological Society type II 
was then conducted.73 The membranous cover layer of the vocal fold was resected 
bilaterally by sharp dissection, with reflection of the epithelium and lamina propria to 
superior and inferior edges of the vocal fold confirmed with exposure of the 
thyroarytenoid muscle. Surgery was performed by the same surgeon in all cases. 
Intraoperatively, the COVR implant was divided in half, with one half of the gel placed 
on either vocal fold for the rabbit implantations, while maintaining appropriate 
directionality of the developed COVR epithelial layer. 
Immediately following surgical resection, rabbits received one of four treatments: 
11 rabbits received hASC Injection directly into the remaining vocal fold structure, 
receiving approximately 600,000 cells per side. 13 rabbits received COVR implants, 
which were placed superficially over the thyroarytenoid muscle with the bulk of the gel 
overlying the medial vocal fold. The COVR implant was then secured with sutures at the 
corners of the gel. 12 rabbits received DECELL implants which were placed similarly. 12 
rabbits in the SCAR treatment group had removal of the mucosal membrane only with 
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cupped forceps and served as injured controls. Care to achieve appropriate hemostasis 
was taken. Following the intervention, the rabbits received corticosteroid, proton pump 
inhibitor, and subcutaneous pain medication for 48 hours in addition to a 10-day 
antibiotic course. At 6 weeks the rabbits were euthanized, and larynges were harvested. 
Two of the animals died prematurely. One COVR group animal died 2 days after 
implantation. At autopsy, food was found at the laryngeal inlet, and cause of death was 
attributed to aspiration and asphyxiation. One animal in the SCAR group died 
immediately post-operatively and was attributed to ketamine reaction. Further animals 
did not receive this medication.  
Pig Laryngeal Surgery and COVR implantation 
Three Yucatan Mini pigs, aged 12-18 weeks and weighing 13-26 kg, were 
anesthetized via combined masked and chemical induction with intraoperative 
maintenance of isoflurane. The preferred transoral endoscopic approach for intervention 
under direct visualization was attempted initially. Both the SCAR and hASC Injection 
treatments were successfully completed via direct endoscopy. However, the anatomy of 
the pig’s airway, particularly the pig’s deep larynx and narrow pharynx, made it difficult 
to perform the fine physical maneuvers required for optimal positioning of COVR 
implantation. The COVR implantation was converted to an open transcervical approach 
as described in the rabbit surgery above. Surgical interventions of the vocal fold mucosa 
were unilateral with a single, unaltered COVR gel implanted to the vocal fold. The 
remaining vocal fold was unaltered and served as control vocal fold.  
Following surgical dissection, the three pigs were each placed into a treatment 
group. One pig received hASC Injection of approximately 600,000 cells in the injured 
vocal fold, to provide equivalent cell number to the COVR. One pig received no 
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treatment and served as a SCAR control. The last pig received the COVR implant placed 
superficially with four sutures at the corners of the COVR implant to secure it in position. 
At 6 months, terminal surgery included intraoperative in vivo phonation recorded via 
high-speed camera. Pigs were subsequently euthanized, and larynges were harvested.  
The COVR pig developed rapid neurologic decline and death at 6 weeks post-op. 
On autopsy, the cause of death was determined to be an endemic porcine infection, most 
likely a strain of Streptococcus suis. The pig had been immunosuppressed which was 
thought to be a factor in its death. Because of the circumstances, in vivo phonation was 
not available for this animal.  
Microscopy  
All rabbit larynges were formalin-fixed, paraffin-embedded, and sectioned. 
Histological sections of the bilateral vocal folds were stained with hematoxylin and eosin 
(H&E), MOVAT pentachrome (MOVAT), Anti-Human Leukocyte Antigen (HLA), 
Anti-Bovine Serum Albumin (BSA), and 4′,6-diamidino-2-phenylindole (DAPI). 
MOVAT stain is commonly used for connective tissue staining and includes a mix of five 
stains: alcian blue, Verhoeff hematoxylin, crocein scarlet combined with acidic fuchsine 
and saffron.  
Light Microscopy  
The H&E and MOVAT pentachrome sections were evaluated by light microscope 
to assess the presence of collagen, glycosaminoglycans (GAG), fat, fibrin, infiltrate, and 
irregular epithelium. Infiltrate was described as none, present, or infiltrate plus dependent 
on the amount of white blood cells found within the section. Secondary review of select 
slides were reviewed by a blinded head and neck pathologist for histological 
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confirmation. The COVR group rabbit that died prematurely following the implantation 
was not included in the results or analysis.  
Fluorescent microscopy 
 Rabbits were stained with DAPI fluorescent dye, used to visualize nuclei and 
additionally dyed with either HLA or BSA. The hASCs were confirmed to stain and 
fluoresce with HLA. As the COVR and hASC Injection treatments both used human 
derived stem cells, HLA fluorescence was used to determine survivability of the hASCs. 
BSA served as a negative control. 
Nonlinear scanning laser microscopy (NSLM)  
NLSM imaging can capture both second harmonic generation (SHG) and two-
photon fluorescence (TPF). SHG imaging captures images based on the scattering of 
photons that are collected, while TPF uses fluorescent emissions for image detection and 
capture.74 NLSM has been previously used in pig vocal folds to visualize, quantify, and 
define orientation of both Type I and Type III collagen, as well as elastin.75,76 For NSLM 
imaging unstained, paraffin fixed slides of pig vocal fold tissue were created from both 
the treated and untreated cords of each pig. NSLM imaging was performed on a custom 
Leica Sp8-MP-DIVE confocal microscope system with imaging of both SHG and TPF 
image detection and capture recorded simultaneously. SHG was used to visualize 
collagen and TPF to visualize elastin. Images were collected using a 20x dry lens, with 
10 percent overlap of images with live imaging averages during acquisition. SHG was 
captured at 400-420nm and TPF was captures at 497-567 nm wavelengths. Microscope 
imaging and capture details, including power of SHG and TPF lasers, line and frame 
averages, and acquisition depth were based on trial and error. The hASC Injection and 
SCAR treated pig vocal folds were imaged to include all scannable section from the 
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epithelium to just beneath the transition of the musculature, capturing the entirety of the 
vocal fold cover layer. These pig cover layers areas of interest were confirmed with H&E 
and MOVAT pentachrome stained sections. The COVR treated pig vocal fold sections 
were imaged in their entirety. 
We performed a modified approach to the imaging and data analysis initially 
described in in Miri et al. 2012.75 Specimen imaging of the mucosa layer included all 
epithelium and lamina propria layers up to and including the interface of the 
thyroarytenoid musculature. Image analysis was completed using Image J software. The 
images were processed through Image J using the preinstalled automated image 
thresholding and then processed by the automated percent area fraction programs and 
outputs were recorded. Superficial and deep LP layers were distinguished based on 
anatomical relationships to epithelial and musculature borders, respectively, as described 
in the literature.12,77 Vocal fold images that were either purely musculature or between 
confirmed superficial and deep lamina propia layers were labeled indeterminant. Raw 
images were processed manually to include regions of interest in the superficial and deep 
lamina propria to exclude any portion of epithelium or musculature within the captured 
images. A representative image of the SHG and TPF NLSM captured images and the 
Image J processed regions of interest can be found in Figure 2.  
Collagen and elastin levels, as reflected by the percent area fraction, in both the 
superficial lamina propia (SLP) and deep lamina propria (DLP) were recorded. A 
collagen-to-elastin ratio, reflecting percent area fraction collagen divided by percent area 
elastin for each image was also collected. Direct intra-animal comparison between treated 
and untreated vocal fold of each pig was analyzed. Representative images of the H&E, 
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MOVAT pentachrome, and NLSM imaging of collagen and elastin in the SLP and DLP 
layers can be found in Figure 3. 
 
RESULTS  
Aim 1 Results: 
Light microscopy representative images of rabbit vocal fold sections stained with 
H&E and MOVAT pentachrome can be found in Figure 4. Representative fluorescent 
microscopy images of rabbit vocal folds stained with HLA + DAPI and BSA + DAPI can 
be found in Figure 5. 
COVR (n=12): 
Collagen was present in 50 percent of the sections and was generally described as 
either thin or wavy and rarely thick and bundled. Appreciable fibrin was present in only 
17 percent of vocal folds, was found deep to the epithelium, was small, with well-defined 
borders, and slightly eosinophilic. GAGs were found in 50 percent of the sections and 
was present throughout the vocal fold sections. Fat was present in 25 percent sections. 
Infiltrate was found in 50 percent of the sections, all infiltrates were described as present 
with no infiltrate plus noted. Irregular epithelium was noted on 25 percent of sections. All 
twelve sections of the COVR group rabbits stained positive for HLA and negative for 
BSA.  
DECELL (n=12):  
Collagen was present in 67 percent and was described as wavy, aligned, and 
occasionally thick and bundled. Fibrin was present in 67 percent of the sections. The 
fibrin within the DECELL sections were large, stained darkly eosinophilic, had clearly 
defined edges, and were located at or near remnant sutures. In only one section, 8 
percent, had GAG stain positive within the vocal folds. Fat was not present in any 
 
   
17  
laryngeal sections. Infiltrate was present in 83 percent of sections with two sections, 17 
percent, described as infiltrate plus. Irregular epithelium was noted in 25 percent of 
sections. No sections of the DECELL group stained positive for either HLA or BSA.  
hASC Injection (n=11):  
Collagen was present in 82 percent of sections and was primarily described as 
deep, dense, and bundled. Fibrin was present in 18 percent of sections and described as 
amorphous and slightly eosinophilic. In only one section, 9 percent, stained positively for 
GAGs. Fat was present in 55 percent of sections. Infiltrate was present in 45 percent of 
all sections, with 27 percent described as infiltrate plus and the remaining 18 percent as 
infiltrate present. Irregular epithelium was noted in one section, 9 percent. All twelve 
hASC Injection sections stained positive for HLA, no section stained positive for BSA.  
SCAR (n=12):  
Collagen was present in 83 percent of the sections and was primarily described as 
heavy and disorganized. Fibrin was present in one section, 8 percent, and described as 
amorphous and slightly eosinophilic. GAGs were stained positive in 25 percent of the 
sections. Fat found in 42 percent of sections. Infiltrate was noted in 42 percent, with no 
sections described as infiltrate plus. Irregular epithelium in was found in 17 percent of 
sections. No sections of the SCAR group stained positive for either HLA or BSA.  
Aim 2 Results:  
Nonlinear scanning laser microscopy (NLSM) values of percent area fraction of 
collagen and elastin, and the calculated collagen-to-elastin ratio of each Pig vocal folds in 
the three treatment arms, hASC Injection, SCAR, and COVR, were compared directly.  
hASC Injection treatment pig:  
hASC Injection treated vocal folds (hASC) yielded 38 total images which were 
categorized as superficial lamina propia (SLP) (n=12), deep lamina propria (DLP) (n=6), 
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and indeterminant lamina propria (n=20). The control vocal fold (CTL) yielded 42 total 
images: 6 SLP images, 6 DLP images, and 30 indeterminant images. Percent area fraction 
findings of both elastin and collagen, and collagen-to-elastin ratio data found in Figure 6. 
SLP and DLP percent area fractions of both the CTL and hASC treated vocal 
folds were compared. The  CTL fold had significantly greater collagen area fraction in 
the DLP than in SLP (10.1±3.6 and 5.0±2.5%, p<0.01 two-way ANOVA). The collagen-
to-elastin ratio was significantly higher in the DLP than the SLP (0.40±0.07 and 0.21 
±0.31, p<0.01 two-way ANOVA). The  hASC vocal folds had significantly increased 
collagen area fraction in the SLP than DLP (27.1±6.4% and 14.6 ±4.6%, P<0.001 two-
way ANOVA). The hASC Injection collagen-to-elastin ratio was significantly greater in 
the SLP than in the DLP (1.2±0.3% and 0.2±0.08%, p<0.001 two-way ANOVA). Elastin 
was not significantly different between the SLP and DLP in either the CTL or hASC 
vocal folds.  
Comparisons between the CTL and hASC treated vocal fold SLP and DLP were 
analyzed. In the SLP, collagen percent area fraction was significantly greater in the hASC 
group than in the CTL fold (27.1±6.4% and 5.0±2.5%, p<0.001 two-way ANOVA). 
Additionally, the SLP collagen-to-elastin ratio was greater in the hASC Injection fold 
than in the CTL fold (1.2±0.3% and 0.2±0.08%, p<0.001 two-way ANOVA). There was 
no significant difference in the elastin percent area fraction in SLP. Within the DLP, the 
hASC Injection treated vocal fold had a higher collagen percent area fraction than the 
CTL fold, that was approaching but did not reach significance (p = 0.07, two-way 
ANOVA). However, the collagen-to-elastin ration in the hASC was greater significantly 
greater than the CTL fold DLP (0.5±0.1 and 0.04±0.07%, p<0.05 two-way ANOVA).  
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SCAR treatment pig:  
Scarred vocal folds (SCAR) imaging yielded 54 total images, 18 SLP, 20 DLP, 
and 16 indeterminant images. CTL yielded 58 total images, 18 SLP, 13 DLP, and 27 
indeterminant images. Percent area fraction findings of both elastin and collagen, and 
collagen-to-elastin ratio data can be found in Figure 7. 
 Within the CTL vocal fold, the SLP had significantly increased collagen percent 
area fraction (12.9±4.6% and 4.5±2.2%, p<.001 two-way ANOVA) and elastin percent 
area fraction (31.0±9.2% and 16.1±4.2%, p<0.001 two-way ANOVA) compared to the 
DLP.  The collagen-to-elastin ratio in the SLP was increased compared to the ratio DLP 
but did not reach significance (0.4±0.2 and 0.3±0.2, P = 0.054 two-way ANOVA).  
 Pig 2’s SCAR treatment had significant differences in both the superficial and 
deep lamina propia. Compared to CTL the SLP elastin was significantly lower 
(21.0±5.9% and 31.0±9.2, p<0.001 two-way ANOVA). The collagen-to-elastin ratio was 
also significantly increased in the SCAR SLP than in the CTL fold (0.7±0.3% and 
0.6±0.2, p<0.001 two-way ANOVA). There was no significant difference in the collagen 
levels between the SCAR and CTL within SLP.  In the deep lamina propia, the SCAR 
fold had increased collagen percent area fraction (12.8±5.1% and 4.5±2.2%, p<0.001 
two-way ANOVA). The collagen-to-elastin ratio was also significantly increased in the 
SCAR fold compared to the CTL (0.7±0.3% and 0.3±0.2, p<0.001, two-way ANOVA). 
There was no significant difference in DLP elastin levels between the SCAR and CTL 
folds.  
COVR treatment pig:  
COVR treated vocal folds (COVR) imaging yielded 1048 images, 64 SLP, 28 
DLP, and 956 of the remaining images were indeterminant or contained only 
 
   
20  
musculature. CTL yielded 334 total images, 26 SLP, 24 DLP, 284 were indeterminant or 
musculature only. Percent area fraction findings of both elastin and collagen, and 
collagen-to-elastin ratio data can be found in Figure 8 Additionally, representative H&E 
and MOVAT pentachrome stained sections and NLSM imaging of both control and 
COVR treated vocal folds can be found in Figure 9. 
 Within the CTL fold, the collagen percent area fraction within the SLP was 
significantly higher than the DLP (21.4±9.8% and 11.2±4.5%, p<0.001 two-way 
ANOVA). The elastin percent area fraction was significantly greater in the DLP than the 
SLP (20.7±6.9% and 11.3±10.2%, p<0.001 two-way ANOVA). The collagen-to-elastin 
ratio was significantly larger in the CTL SLP than the DLP (4.4±4.7% and 0.7±1.1%, 
p<0.001 two-way ANOVA). Within the COVR folds, there were no significant 
differences in the percent area fraction of either the collagen and elastin, nor in the 
collagen-to-elastin ratio between the SLP and DLP. 
 Pig 3’s COVR treatment had significant differences in both the superficial and 
deep lamina propia, compared to the CTL fold. Comparing the SLP, the collagen was 
significantly increased in the CTL fold compared to the COVR fold (21.4±9.8% and 
8.1±3.4%, p<0.001 two-way ANOVA). The elastin in the COVR SLP was also higher 
than in the CTL (17.7±8.6% and 11.3±10.2, p<0.01 two-way ANOVA). The collagen-to-
elastin ratio was significantly larger in the CTL SLP than the COVR SLP (4.4±4.7% and 
0.7±1.1, p<0.001 two-way ANOVA). The DLP collagen percent area fraction was 
significantly larger in the COVR group than the CTL (11.2±4.5% and 7.5±3.3%, p<0.01 
two-way ANOVA). There was no significant difference between the COVR and CTL 
DLP with respect to the elastin and collagen-to-elastin ratio.  
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 A comparison image of percent area fractions and collagen-to-elastin ratio of the 
superficial layers of all three pigs can be found in Figure 10. 
DISCUSSION 
Dysphonia has a sizable health care cost burden and has significant negative 
effects in the lives of those affected. Optimal treatment for the disruption of the vocal 
fold microstructure in dysphonia caused by severe vocal fold scarring remains elusive 
and attempts at improving the healing process to improve vocal quality has proved 
challenging. Surgical resection and cold steel interventions often redevelops scar tissue 
through normal wound healing, while injectable therapies of biologic and bioactive 
materials have led to limited success in the development of appropriate extracellular 
matrix and improved functional outcomes.  
Despite decades of attempts, scarred vocal folds remain difficult to repair. 
Regenerative medicine techniques to restore native tissue or replace structures with 
functionally identical tissue, provides an avenue of therapeutics that may best address the 
challenge of vocal fold scarring. Multiple cell and biologic therapies have shown 
preclinical success, with three recent human clinical trials demonstrating encouraging 
safety profiles and improved objectively gathered results.67-69 Overall, subjective 
improvements in vocal quality, as reported by patients on the vocal health index (VHI) 
has also been encouraging, though less consistent. In patients who received injected 
autologous fibroblasts as treatment, VHI improved, but failed to reach statistical 
significance.68  In patients who received autologous mesenchymal cell injections, only 
half of them showed improvement on the VHI.69 Some stem cell injections lack 
persistence, including some mesenchymal stem cells that have been noted to die within 
24 hours following injection. Furthermore, treatment is limited by scar size, such that 
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larger defects cannot be fully regenerated by injection.78-80 Together, this provides a 
limited therapeutic treatment window and time-limited effectiveness of immune 
modulation. The approach we take on replacing the damaged vocal fold mucosa entirely 
with the COVR implant directly addresses the concerns raised by these clinical trials. 
Aim 1 - Histology of COVR and Components 
Collagen 
 We compared the histologic findings of the intermediate-term implantation of 
COVR, and the COVR components, a decellularized fibrin matrix and the human 
adipose-derived stem cells within rabbit vocal folds to elucidate the benefits and method 
of action that the COVR implant has in wound healing and scar formation. When 
comparing hematoxylin and eosin, as well as Movat pentachrome stained sections, 
patterns emerge within the healing cycle. Overall analysis of the rabbit laryngeal section 
histology provide evidence that intermediate term COVR implantation inhibits scar 
formation when compared to the separated COVR components, decellularized scaffold 
and direct hASC Injections, as well as non-treated scar control. On review, the COVR 
and DECELL group had notably fewer total sections stain positively for increased 
collagen than the hASC Injection and Scar treatment groups. The collagen in both the 
DECELL and COVR groups was also more often described as thin and wavy, while the 
hASC Injection laryngeal sections were more often described as thick and bundled or 
disorganized, the hallmark description of histologic fibrosis.18 It is possible that the wavy 
collagen will continue remodeling to become organized and cross-linked, functionally 
normal collagen, however, scar tissue formation and collagen remodeling can take up to 2 
months.25 Thus longer implantation and histological follow-up is required to confirm the 
ultimate fate of this collagen. Nonetheless, the decreased collagen levels and favorable 
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description of this collagen supports the finding that the COVR implant attenuates scar 
tissue formation that is maintained after intermediate-term implantation.  
Inflammatory Response  
In comparing the inflammatory response, an infiltrative process was present in a 
majority of the DECELL group and half or less of all sections in the COVR, hASC 
Injection, and SCAR treatment groups. However, the hASC Injection and DECELL 
groups had multiple sections described as having a continued robust white cell presence 
at six weeks, while both the COVR and SCAR group both had no sections with this level 
of immune response. The DECELL group’s inflammatory response raises the question of 
an inflammatory response to the decellularization process. Indeed, residual SDS can 
cause a severe inflammatory response, however, the infiltrate in our sections lacks the 
encapsulation, giant cells, or hemosiderin-laden cells as previously described, making 
this explanation unlikely.81 Instead, we propose that the lymphocytic reaction in the 
DECELL group more likely resembles a foreign body immune response. Mesenchymal 
stem cells have low immunogenicity, while fibrin as a standalone therapy and as a 
medium for cell introduction, is known to promote faster wound healing through 
angiogenesis, improved cell viability, proliferation and differentiation, and excellent 
integration into surrounding tissue.82,83 Our data indicates that xenographic ASCs 
implants maintain an immunomodulatory effect on surrounding tissue up to six weeks 
and have an improved attenuating influence when embedded within a fibrin matrix than 
when introduced into tissue by direct injection alone.  
 Glycosaminoglycans  
As mentioned previously, the levels of GAGs in the vocal fold are critically 
important for normal function. HA is the most abundant glycosaminoglycan in the folds, 
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is a reliable marker of good healing in the vocal folds, and stains with the pentachrome 
used in this study.33 The COVR group sections stained positively for HA in six of the 
twelve sections sections and the SCAR group stained positively for HA in a three of 
twelve sections, while the DECELL and hASC Injection groups both stained positively 
for HA in only one section. The mechanism of GAG deposition, whether GAG derives 
from the introduced ASC or native tissue, is unclear. Mesenchymal stem cells have HA 
synthase and have been implicated in HA deposition in autologous bone marrow derived 
MSC transplants in mice larynges and allogenic laryngeal mucosa derived MSC 
transplants in canine larynges.84,85  Given that this was a xenographic treatment after 
removal of native tissue, it is likely that introduced ASCs synthesize their own GAG, but 
we cannot rule out stimulation of intrinsic GAG synthesis. The relative deficit of GAG in 
the hASC Injection and DECELL groups may be explained by the prolonged incubation 
during COVR development, during which GAGs may be synthesized and retained within 
the scaffold. Additionally, the fibrin gel may play a protective role of the embedded cells, 
limiting the lymphocytic response and clearing of the COVR cells, from which the 
injected cells do not benefit. In either case, our data indicates that ASCs embedded within 
a scaffold, but not directly injected into damaged mucosa, leads to improved GAG 
deposition into the ECM at six weeks, reflecting improved wound healing and a more 
normal ECM microstructure. This improvement of microstructure suggests improved 
biomechanical properties which may have implication on functional outcomes of the 
COVR treated vocal folds. The significance of the six COVR sections that did not stain 
for HA is unclear, further studies are needed to confirm if the HA positivity has an effect 
on voicing. 
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HLA staining 
 Previous research in this laboratory has shown persistence of autologous adipose-
derived stem cells at four weeks embedded in fibrin gel scaffold.86 The rabbit fluoroscopy 
imaging of positive HLA-staining cells indicates that xenographic implantation of human 
ASC implanted in rabbit vocal folds persists up to six weeks whether embedded within a 
fibrin gel structure or directly injected into the vocal fold. Additionally, there was a 
greater HLA positivity in the COVR fluorescent images than in the hASC Injection 
sections. There was no such positive staining in the DECELL gel structure. The increased 
stem cell persistence in the COVR group compared to hASC Injection further supports a 
protective benefit of the fibrin scaffold in overall cell survival and may suggests 
increased proliferation of embedded cells, previously described in keratinocytes and 
fibroblasts.87 Further analysis is required to understand whether these cells arise from 
improved survivability of originally embedded cells, increased proliferation of cell 
lineages, or a combination of both.  
Fibrin  
There were clear differences in the fibrin appearance and amount between the 
treatment arms. The fibrin within the DECELL sections had well circumscribed, deeply 
eosinophilic structures. When compared to the H&E laryngeal sections of the animal that 
received COVR implant and died post-operatively, the DECELL larynges appeared 
identical. We suspect then that the DECELL fibrin is retained fibrin from the implanted 
gel structures. The fibrin in the COVR treated laryngeal sections had less clear gel 
remnant and more closely resembled the fibrin found in both the hASC Injection and 
SCAR groups. The COVR sections likely had a mixture of the remnant fibrin scaffold 
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and fibrin of residual wound healing, while the SCAR and hASC Injection was solely 
lingering wound healing fibrin.  
All treatment arms had presence of other findings, such as a presence of dispersed 
fat cells and irregular epithelium, though there were too few cases to make any conjecture 
on their implications, if any. 
Aim 2 -NLSM imaging of pig vocal folds 
 Nonlinear scanning laser microscopy (NSLM), also called two-photon 
microscopy or multi-photon microscopy, pulses two photons that simultaneously interact 
with a molecule causing excitation, the resulting emission is then recorded as normal.88 
Each of the NSLM photons are typically half the energy of a single-photon system, such 
as in fluorescent microscopy, which minimizes the damage caused to tissue by higher 
energy photons while simultaneously improving image detection.89 This allows for 
excellent imaging of the vocal fold microstructure including the elastin and collagen 
within the vocal folds, without the need to alter the tissues for imaging. Analysis of 
treated vocal fold extracellular matrix collagen and elastin levels and calculated collagen-
to-elastin ratio were compared to the control, unaltered contralateral folds in the three 
treatment arms: hASC Injection, SCAR, and COVR implantation. Notably, there was no 
attempt or intervention to enforce voice rest in these animals following their operation, 
which is usual treatment in humans following vocal fold scar resection. 
hASC Injection  
The pig that received hASC Injection had control vocal folds with collagen, 
elastin, and collagen-to-elastin ratios in the layer and concentrations distribution 
described in the literature. The control fold had significantly greater collagen levels in the 
deep lamina propria than in the superficial layer. The vocal fold that received hASC 
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Injection had significantly increased collagen deposition in the superficial lamina propria 
layer, similar to that seen in the rabbit histology, however this was not appreciated on 
light microscopy of the pig vocal fold. The fibrosis indicates an increased inflammatory 
response during healing, although no white blood cells were present in light microscopy 
or in the NLSM images. This is likely due to the longer post-operative healing period 
prior to laryngeal harvest. Voice rest during acute wound healing with gradual vocal fold 
use has been noted to improve vocal fold wound healing and voice quality outcomes in 
humans, while uncontrolled voice use worsens outcomes.90-92 We propose that the 
unrestricted animal’s spontaneous phonations led to increased stress at the vocal fold 
surface prior to epithelialization, which worsened acute wound healing and led to more 
more fibrosed superficial lamina propria. 
When comparing the hASC Injection treated and untreated vocal folds we found 
significantly increased collagen deposition in the superficial layer and an increased and 
non-significant though increased collagen deposition within the deep layer. Interestingly, 
the magnitude of collagen increase in the superficial layer was much greater than in the 
deep, suggesting that the hASC does have wound healing benefits that are more present 
within the deep but not superficial layers of lamina propria. This is further evidenced by 
an improved collagen-to-elastin ratio within the deep lamina propia and worsened 
collagen-to-elastin ratio in the superficial lamina propria.  The decreased fibrosis may 
signal that the ASCs have their greatest immunomodulatory benefit at or near their 
injection site, the thyroarytenoid muscle, and a weakened effect more superficially. There 
were no significant differences between the elastin levels in the control versus treatment 
vocal folds in either the superficial or deep lamina propria. This is consistent with 
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previous findings of elastin levels returning to baseline at 6 months following injury.34 
Overall, the increased collagen deposition indicates increased fibrosis and poor healing 
following hASC Injection alone. Functionally, the superficial lamina propria is more 
directly involved in sound production and vocal quality and we would expect a poorer 
functional outcome in this pig.  
SCAR Pig  
The pig that received mucosal resection without intervention had an interesting 
baseline vocal fold structure. NLSM imaging of the control fold showed significantly 
increased baseline collagen levels and elastin levels in the superficial lamina propria, and 
an increased collagen-to-elastin ratio that was also approaching significance. The scarred 
vocal fold was more uniform, lacking any significant difference in total collagen or 
elastin between the two lamina propria layers. Comparing the scar and control folds, the 
elastin levels in the scarred fold was significantly decreased in the superficial lamina 
propria. Within the deep lamina propria, the scarred fold showed significantly increased 
collagen levels, as expected. Our findings support previously document decreases in 
elastin levels in scarred folds and collagen deposition in the deep lamina propria.34,48 
Moreover, the baseline findings in this animal’s control fold illustrate the importance of 
evaluating collagen structure and organization, not purely overall levels, when 
determining scar tissue in histology.  
COVR Pig  
The pig that received the COVR implant died six weeks after the intervention 
from an indolent Streptococcus Suis infection that was exacerbated by postoperative 
immunosuppression. NLSM imaging analysis of the control vocal fold identified 
significantly increased collagen in the superficial layer and significantly increased elastin 
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in the deep lamina propria, which we believe reflects injury to the control vocal fold. This 
is not surprising as we transitioned to an open surgical approach during COVR 
implantation which we may have led to some collateral damage, not seen in the other pigs 
that underwent an endoscopic intervention.  
Interestingly, the COVR treated vocal folds were more uniform, as there were no 
significant differences between the superficial lamina propria compared to the deep layer. 
While epithelialization occurs during COVR development, this data supports a delayed 
division of the mucosal layers that occurs beyond six weeks following implantation.  
Comparing the treated and untreated folds, the superficial lamina propria of the COVR 
fold had significantly decreased collagen deposition, increased elastin levels, and an 
improved collagen-to-elastin ratio than the control. While mature scar formation may 
take up to a year in the vocal folds, postinjury collagen synthesis is greatest during the 
first six weeks of healing, and the SHG imaging modality is sensitive to both Type I and 
Type III collagen, which predominate early scar formation.25,34,75 Thus our data suggests 
that COVR implantation improves wound healing at six weeks, which we expect will 
improve longer durations of healing as well. 
In the deep lamina propria, the COVR implant had increased collagen deposition 
compared to the control fold. During COVR development, a layer of hASCs is added to 
the superior, non-immersed surface of the gel, which becomes the epithelial layer. As this 
animal had only six weeks of COVR implantation, we would expect continued 
persistence of hASCs greater at the epithelium and superficial lamina propria, as seen in 
the rabbit HLA histology. A greater number of bioactive stem cells would therefore have 
improved healing effects within the superficial lamina propria and less of an effect within 
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the deep lamina propria. In addition, initial healing and implant grafting would occur at 
the juncture of thyroarytenoid musculature and COVR implant, which would help explain 
the increased collagen deposition in the deep lamina propria. Although long-term COVR 
implantation is needed to confirm that fibrosis indeed remains limited in the superficial 
lamina propria with this therapy, our preliminary findings are encouraging. Furthermore, 
additional methodologies are needed to understand the long term structural and functional 
improvements that COVR treated larynges have on voice production and vocal quality.  
Superficial Lamina Propria treatment comparisons  
Contrasting the superficial lamina propria in the three treatment arms and their 
respective controls further produced interesting findings. Contrary to expectation, the 
hASC Injection pig, but not the SCAR pig, had a significantly increased amount of 
collagen at six months. hASC cell injections as a treatment for vocal fold scarring leads 
to improved collagen deposition in preclinical and clinical applications and is associated 
with improvement in functional outcomes. A limitation of the NLSM imaging analysis in 
this study is our reliance on quantifying the amount of collagen present, but not 
describing nor account for the organization of the collagen fibers measured. As such, we 
believe the percent area fraction of collagen, to infer levels of collagen, is a poor marker 
of fibrosis if collagen organization is not taken into account. The calculated collagen-to-
elastin ratio is also heavily influenced by the collagen percent area fraction and was not 
found to be a useful as a marker of fibrosis or comparison between animals. Instead, we 
argue that decreased elastin is a more sensitive marker of fibrosis and improved healing 
in NLSM imaging. In comparing elastin levels, we find the SCAR pig has the worst 
outcome, as expected. The hASC Injection elastin levels are equivalent to control fold 
levels and therefore suggest improved healing compared to scar. The COVR treatment 
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had a significantly increased elastin level in the treated vocal fold also suggesting 
improved healing, albeit at a shorter post-operative endpoint.  
Comparisons of the deep lamina propria layers between the treatment and control 
for the three treatment arms had increased collagen deposition for the SCAR and COVR 
treated folds only. While statistically significant, vocal fold functionality and voice 
production relies heavily on the cover portion of the vocal fold and less so on the body, to 
which the deep lamina propria belongs. Thus, we expect that these increases in collagen 
deposition would have minimal influence on voice quality and production, if any. We 
suggest that future NLSM microstructure imaging focus on the superficial lamina propria, 
and intermediate lamina propria where applicable. 
Our preliminary findings suggests that the COVR implant, as a complete mucosal 
replacement, improves overall wound healing with decreased fibrosis and intermediate-
term ECM microstructure. This histologic analysis is limited by the subjective nature of 
image analysis and the imperfect method of translating images to an absolute value; thus, 
biochemical analysis is underway of the rabbit harvested larynges. Through enzymatic 
cell digestion of all harvested rabbit vocal fold sections, we hope to identify cytokine, 
mRNA, and ECM components and determine absolute quantitative values of 
glycosaminoglycans, collagen, and fibrin, to correlate with the imaging analysis 
performed here. Together, this will better elucidate the method of actions of the COVR 
components, particularly the hASC’s role in immunomodulation and wound healing. 
Additionally, ECM collagen and elastin levels within the pig laryngeal sections will be 
identified and quantified by cell digestion to correlate with the imaging data presented 
here. 
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It remains to be seen if the histological improvements in the rabbit and pig 
laryngeal sections translate to functional improvement following COVR implantation. 
This laboratory is currently pursuing additional methods of analysis of pigs involved in 
this study. Pig spontaneous in vivo phonations were recorded prior to their operations and 
during the weeks to months following their interventions until their termination. During 
the terminal surgery, the animals underwent induced in vivo phonation during which we 
recorded the sound production and concurrent high-speed video recordings of the vocal 
folds, with the notable exception of the COVR pig. These high-speed video recordings 
will be analyzed for stroboscopy and mucosal wave analysis, commonly used methods of 
vocal fold functional assessment both clinically and in animal research. The acoustic 
analysis of the audio recordings at various timepoints pre- and post-surgery, will allow us 
to determine what acoustic improvements, if any, occur following each intervention and 
how these change over time. It is the hope of this laboratory to create a robust voicing 
animal model for COVR implantation to advance this treatment as a therapeutic option 
for patients. 
CONCLUSION 
Animals that received COVR, a human-derived adipose stem cell-based gel 
implant, better regulate healing and scar development following intervention than those 
which received cells only, fibrin gel only, or were scar controls. In rabbits, COVR 
implantation promotes improved healing and decreased scarring at six weeks, as 
supported by the increased hyaluronic acid deposition and decreased collagen 
development. Xenograph ASCs grafts persist weeks and have continued 
immunomodulatory effects up to six weeks following implantation. ASC 
immunomodulatory effects are increased effects when embedded in a fibrin gel than 
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when directly injected into damaged vocal folds. Decreases of overall elastin levels are 
more sensitive marker of fibrosis in non-linear scanning microscopy imaging than 
increases in collagen levels. Further research is needed to determine if histologic 
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